Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.

Pulmonary Therapy
David M G HalpinDavid A Lipson

Abstract

In the IMPACT trial, single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced moderate/severe exacerbation rates versus FF/VI or UMEC/VI dual therapy in patients with chronic obstructive pulmonary disease (COPD); however, pneumonia incidence was higher in FF-containing arms. As COPD is a growing problem in Asia, we compared the efficacy and safety of FF/UMEC/VI in Asia versus non-Asia regions. IMPACT was a double-blind, 52-week trial in symptomatic COPD patients with ≥ 1 moderate/severe exacerbation in the prior year. This pre-specified analysis evaluated the annual rate of moderate/severe exacerbations, change from baseline in trough forced expiratory volume in 1 s, and St George's Respiratory Questionnaire total score, mortality, and safety (including pneumonia) in Asia versus non-Asia regions. The intent-to-treat population comprised 10,355 patients (Asia n = 1644 [16%]). Rate ratios (95% confidence intervals) for moderate/severe exacerbations with FF/UMEC/VI were 0.89 (0.76-1.05) versus FF/VI and 0.86 (0.71-1.04) versus UMEC/VI in Asia, and 0.84 (0.79-0.90) and 0.74 (0.68-0.80) in non-Asia. Efficacy of FF/UMEC/VI on other endpoints was similar in both regions. There was an increased inc...Continue Reading

References

Dec 4, 2003·Lancet·Shinji TeramotoYasuyoshi Ouchi
Apr 9, 2004·Lancet·Amy Berrington de González, Sarah Darby
Sep 15, 2004·Respirology : Official Journal of the Asian Pacific Society of Respirology·Koichiro TatsumiUNKNOWN Respiratory Failure Research Group in Japan
Dec 2, 2006·COPD·Paul W Jones
Feb 7, 2008·Chest·Wan C Tan, Tze P Ng
Jul 11, 2008·Clinical Pharmacology and Therapeutics·S U YasudaS-M Huang
Jan 16, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Wan C TanNan-Shan Zhong
Nov 10, 2009·The European Respiratory Journal·W XuJ Bourbeau
May 5, 2011·Respirology : Official Journal of the Asian Pacific Society of Respirology·Yoshinosuke FukuchiDonald Tashkin
Apr 24, 2012·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Alice MartinSally Hull
May 25, 2012·Respiratory Medicine·Hana MüllerovaJadwiga A Wedzicha
Dec 10, 2014·Annals of the American Thoracic Society·Courtney CrimPeter M A Calverley
Oct 24, 2015·Respirology : Official Journal of the Asian Pacific Society of Respirology·José Luis López-CamposJoan B Soriano
Dec 22, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S Ehteshami-AfsharM Sadatsafavi
Jul 16, 2016·The European Respiratory Journal·Steven J PascoeNeil Barnes
Oct 28, 2016·International Journal of Chronic Obstructive Pulmonary Disease·Shu HashimotoDonald Banerji
Feb 9, 2017·International Journal of Chronic Obstructive Pulmonary Disease·Jadwiga A WedzichaDonald Banerji
Apr 19, 2018·The New England Journal of Medicine·David A LipsonUNKNOWN IMPACT Investigators
Nov 23, 2018·International Journal of Chronic Obstructive Pulmonary Disease·Takeo IshiiPaul Jones
Jul 6, 2019·The European Respiratory Journal·David M G HalpinAlvar Agusti
Jun 25, 2020·The New England Journal of Medicine·Klaus F RabeUNKNOWN ETHOS Investigators

❮ Previous
Next ❯

Citations

Nov 19, 2021·European Respiratory Review : an Official Journal of the European Respiratory Society·Robert A WiseRichard E K Russell

❮ Previous
Next ❯

Software Mentioned

ETHOS
FLAME
UPLIFT
IMPACT
SUMMIT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.